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with clinical events (disease progression or tumor response) or changes 
in patient functioning (i.e., performance status). 
Methods: Eighty patients with advanced NSCLC (median age = 70.5 
years) were prospectively studied during the ﬁrst 12 weeks of their che-
motherapy. Eligibility criteria included diagnosis of new or recurrent 
stage III or IV NSCLC, initiation of chemotherapy (any line), over age 
18, comprehension of English, and no substantial cognitive or physi-
cal impairments. Symptoms were assessed weekly through telephone 
administration of the Functional Assessment of Cancer Therapy Lung 
Symptom Index-12 (FLSI-12), a brief, reliable and valid symptom 
measure for advanced lung cancer, with items scaled from 0 (not at 
all) to 4 (very much). Based on FLSI-12 item scores, all patients were 
at least slightly symptomatic at baseline. Data on Eastern Cooperative 
Oncology Group performance status (PS) were collected from patients 
every three weeks during clinic visits. At baseline, most patients (83%) 
rated themselves PS 0 (normal activity) or PS 1 (symptomatic, fully 
ambulatory). Symptom reports were mapped onto on-study clinical 
events (progression or response) and PS assessments. Disease progres-
sion and tumor response were determined by clinicians from radiologi-
cal evidence using RECIST criteria. 
Results: Several symptoms worsened in association with disease 
progression and declining PS. Disease and chemotherapy-related 
symptoms, such as, pain, shortness of breath, cough, weight loss and 
appetite loss worsened most with disease progression. Patients respond-
ing to chemotherapy reported more fatigue and difﬁculty breathing 
at response than immediately before it. However, unlike the patients 
who progressed, patients responding to chemotherapy never or rarely 
complained of pain, weight loss, cough, chest tightness, nausea, or 
confusion before, during, or after response. Symptoms most associated 
with changes in PS were fatigue, weight loss, nausea, and appetite loss. 
For these, declining PS was associated with considerably more symp-
tom worsening than unchanged or improving PS. However, pulmo-
nary symptoms (shortness of breath, cough, chest tightness, difﬁculty 
breathing) were less clearly associated with changes in PS. 
Conclusions: This study provides some direction that pulmonary 
symptoms and other general symptoms such as pain, loss of appetite 
and weight loss are most closely associated with disease progression. 
Patients responding to chemotherapy are less likely to have worsening 
of their pulmonary symptoms. A larger study may deﬁnitively identify 
changes in disease symptoms associated with disease progression and 
overall survival. Such information could assist clinicians in monitoring 
patient status on treatment and possibly investigate and modify treat-
ment depending on changes in symptom proﬁle.
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Background: Some factors such as age, stage and PS may provide 
prognostic information in advanced NSCLC; however, a better un-
derstanding of a patient’s judgement can help the Physician to make 
appropriate decisions. 
Purpose: 1- To study the information provided by pts in a question-
naire. 2 To study PS evolution obtained by the doctor (DPS) and by 
the pts themselves (PPS).3-To evaluate the correlation between some 
different variables with survival.
Patients and Method: 248 pts with stages III and IV NSCLC, age 
range 38 - 74 years, were studied. The study was prospective. Pts un-
derwent chemotherapy and/ or radiotherapy. They determined their own 
PS through a questionnaire. Some different variables such as age, stage, 
DPS, PSP, appetite, food intake, amount of solid food, evening meals, 
average meal per day, serving size, vomiting frequency, daily work 
activity, activity restrictions, and hours of rest per day were analyzed. 
DPS and PPS were studied at diagnosis and at 3 months. Statistical 
methods: Cox Proportional-Hazards Regression, Chi Square Pearson, 
Irwin-Fisher, Wilcoxon tests and Kaplan Meier Curves were used.
Results: According to the univariate logrank test applied to the com-
parison of the Kaplan and Meier survival curves, many factors seem to 
be related to survival.The correlation among predictor variables is not 
taken into account when using the univariate approach, so a Cox model 
for the proportional risk was ﬁtted using all the predictor variables 
available. A stepwise model selection was applied. It was found that 
only initial WL and DPS at the third month of evaluation were posi-
tively related to the risk of death. 
Conclusion: Although the univariate approach showed that many 
factors are related to the survival of patients, the simultaneous analysis 
of these factors through the Cox model revealed that few of them sum-
marize the most relevant prognostic information. These variables are 
DPS at the third month of evaluation and initial WL.
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Objectives: NGO’s are close to rural coomunities than City-based 
hospitals. Cost of running a NGO far less than medical institution. Cost 
of anti-ancer drugs is debatable at many forums. Pharma co’s dont give 
substantial discounts to patients. In resource poor setting unafford-
able cost leads to poor therapeutic compliance & high mortality. This 
Cost hurdle was overcome using our Community-NGO based model. 
It provides cost-effective methodology. We need to establish com-
mon strategy to develop of sound & sustainable cancer care programs 
avaialble to rural communities
Methods: Our NGO volunteers have strength of 24. cost of chemo-Ra-
dio therapy is beyond reach of common people in developing nations. 
Chemotherapy treatment in ci6ty speciality hospitals is unaffordable. 
No national program for ﬁnancial help to lung cancer patients avail-
able. Some NGO’s’s do offer little psychosocial support & subsidised 
treatment options. But such efforts are not cohesive. I lead team to con-
duct small seminars to mobilise community NGO’s support for Lung 
cancer patients. We work for 10 hours per week free of cost to help 
poor patients for treatment access [illeterate poor patients from villeges 
need guidance & little ﬁnacial help]. Depending on support given by 
corporates & few local donors we give these poor people little ﬁnancial 
assistance to cover treatment cost. We help these patients in getting 
access to governmental hospitals, till today our NGO covered 9 villages 
supporting 64 lung cancer sufferers. 
Results: We did face hiccups in mobilising volunteers & resources. We 
now have ﬁve local community NGO’s integrated program. These can-
